Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Giant Biogene Holding Co., Ltd. (2367.HK)
HKD28.44
+1.54 (+5.72%)
CN HKSE Consumer Defensive Household & Personal Products
Address
No. 1855, Shanglin Yuan
Xi’an, CN
Xi’an, CN
CEO
Jianya Yan
Website
xajuzi.com
IPO
2022-11-04
ISIN KYG3887G1091
Description
Giant Biogene Holding Co., Ltd. operates as an investment holding entity, primarily engaged in the research, development, production, and sale of beauty and wellness products based on bioactive materials throughout the People's Republic of China. The company also manufactures functional foods leveraging rare ginsenosides technology and provides medical devices. Its diverse product range, which includes specialized skincare, medical dressings, and nutritional supplements, is marketed predominantly under brand names such as Comfy, Collgene, Keyu, Kehen, Kefuping, Leeyen, SKIGIN, and Shengan. Established in 2000, Giant Biogene Holding Co., Ltd. maintains its headquarters in Xi'an, PRC.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
HKD28.44
+1.54 (+5.72%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5M
Beta
0.71
Float Shares
476.56M
Free Float %
44.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +11.25% | +8.91% | -0.46% | -5.83% | -16.92% | -9.68% | -57.66% | -15.08% | +12.58% | +12.58% | +12.58% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
28.44
DCF (Unlevered)
162.92
+472.9%
DCF (Levered)
169.05
+494.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
83% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | -2 |
| Buy | 14 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
21.89
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A+
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
3 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Household & Personal Products: +3.3%-0.4% Q4'25: +25.4% (vs Q4'23)
-
EPS growth Household & Personal Products: +8.8%-12.1% Q4'25: -17.1% (vs Q4'23)
-
FCF margin FCF growth · Household & Personal Products: +44.8%+29.9% Q4'25: +42.1% (vs Q4'23)
-
EBIT margin Household & Personal Products: +9.9%+38.4% ★ Q4'25: +31.6% (vs Q4'23)
-
ROIC Household & Personal Products: +8.2%+105.1% ★ Q4'25: +149.5% (vs Q4'23)
-
Share dilution Household & Personal Products: +0.2%+5.8% Q4'25: +11.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Household & Personal Products: -0.51×0.00× ★ Q4'25: 0.00× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 17 Rev. Ana. 9 EPS Ana. |
Dec 2027 17 Rev. Ana. 11 EPS Ana. |
Dec 2028 13 Rev. Ana. 11 EPS Ana. |
Dec 2029 12 Rev. Ana. 4 EPS Ana. |
Dec 2030 6 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.36B
est: 2.50B (-5.3%)
|
3.52B
est: 4.15B (-15.0%)
|
5.54B
est: 5.30B (+4.6%)
|
5.52B
est: 5.55B (-0.6%)
|
6.30B
5.99B – 7.82B
+13.6% YoY
|
7.16B
6.40B – 9.39B
+13.5% YoY
|
8.08B
7.44B – 10.34B
+12.9% YoY
|
13.56B
12.49B – 17.35B
+67.8% YoY
|
15.67B
14.43B – 20.04B
+15.5% YoY
|
| EBITDA |
1.21B
est: 1.36B (-11.5%)
|
1.78B
est: 2.02B (-11.8%)
|
2.31B
est: 2.58B (-10.3%)
|
2.19B
est: 2.70B (-18.6%)
|
3.06B
2.91B – 3.80B
+13.6% YoY
|
3.48B
3.11B – 4.57B
+13.5% YoY
|
3.93B
3.62B – 5.02B
+12.9% YoY
|
6.59B
6.07B – 8.43B
+67.8% YoY
|
7.62B
7.01B – 9.74B
+15.5% YoY
|
| EBIT |
1.18B
est: 1.33B (-11.6%)
|
1.75B
est: 1.97B (-11.4%)
|
2.28B
est: 2.52B (-9.5%)
|
2.12B
est: 2.64B (-19.6%)
|
2.99B
2.85B – 3.72B
+13.6% YoY
|
3.40B
3.04B – 4.46B
+13.5% YoY
|
3.84B
3.53B – 4.91B
+12.9% YoY
|
6.44B
5.93B – 8.24B
+67.8% YoY
|
7.44B
6.85B – 9.52B
+15.5% YoY
|
| Net Income |
1.00B
est: 1.05B (-4.7%)
|
1.45B
est: 1.64B (-11.7%)
|
2.06B
est: 2.06B (0.0%)
|
1.91B
est: 2.19B (-12.7%)
|
2.02B
1.96B – 2.08B
-7.9% YoY
|
2.23B
2.10B – 2.35B
+10.3% YoY
|
2.18B
2.03B – 3.80B
-2.1% YoY
|
4.67B
4.19B – 6.37B
+114.3% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
817.44M
est: 727.66M (+12.3%)
|
1.26B
est: 1.43B (-11.8%)
|
2.16B
est: 1.83B (+18.2%)
|
2.22B
est: 1.91B (+16.2%)
|
2.17B
2.07B – 2.70B
+13.6% YoY
|
2.47B
2.21B – 3.24B
+13.5% YoY
|
2.79B
2.57B – 3.56B
+12.9% YoY
|
4.68B
4.31B – 5.98B
+67.8% YoY
|
5.40B
4.97B – 6.91B
+15.5% YoY
|
| EPS |
0.99
est: 1.10 (-9.8%)
|
1.49
est: 1.69 (-11.8%)
|
2.10
est: 2.00 (+5.1%)
|
1.83
est: 1.93 (-5.1%)
|
1.90
1.85 – 1.96
-1.3% YoY
|
2.11
1.98 – 2.22
+10.9% YoY
|
2.35
1.92 – 3.58
+11.6% YoY
|
4.41
3.96 – 6.01
+87.3% YoY
|
—
— – —
-100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-28 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-27 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-26 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-22 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-21 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-20 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-19 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-18 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-15 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-14 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-13 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-12 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-11 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-06 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
4.41B
OE per share TTM
4.28
Owner's Yield
13.69%
Maintenance CapEx ratio
5.42%
Maint CapEx / Avg PPE
23.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 143 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree China ex-State-Owned Enterprises Fund CXSE | 0.12% | 572.6K | 0.32% |
| 2 | Amundi MSCI China ESG Selection Extra UCITS ETF Dist LHKG.DE | 0.11% | 594.2K | 0.65% |
| 3 | Amundi MSCI China ESG Selection Extra UCITS ETF Acc ASIU.L | 0.11% | 595.0K | 0.65% |
| 4 | Franklin EM Multi-Factor Equity UCITS ETF FREM.L | 0.09% | 80.3K | 0.30% |
| 5 | Amundi Index Solutions SICAV - MSCI China ESG Selection UCITS ETF DR Capitalisation CNEU.L | 0.09% | 192.9K | 0.35% |
| 6 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.09% | 104.6K | 0.42% |
| 7 | HSBC MSCI AC Asia Pacific ex Japan Climate Paris Aligned UCITS ETF USD HPAJ.L | 0.07% | 13.1K | 0.25% |
| 8 | iShares MSCI EM Consumer Growth UCITS ETF CEMG.L | 0.07% | 28.5K | 0.60% |
| 9 | UBS MSCI China Universal UCITS ETF USD dis CNSG.L | 0.06% | 148.1K | 0.30% |
| 10 | Xtrackers MSCI China UCITS ETF 1D XCS7.L | 0.06% | 1.20M | 0.28% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
1.21M
Shares Outstanding
1.06B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Juan Fang | Senior Vice President & Executive Director | 1M | female |
| Juan Ye | Senior Vice President & Executive Director | 1M | female |
| Huijuan Zhang | Chief Financial Officer & Executive Director | 1M | female |
| Jianya Yan | Chief Executive Officer & Executive Chairman of the Board | 877.5K | male |
| Yubo Yan | Chief Product Officer, Joint Company Secretary & Executive Director | 418.0K | female |
| Zhiguang Duan | Senior Vice President | — | male |
| Nelly Au-Yeung | Joint Company Secretary | — | female |
| Wing Yan Yuen FCIS | Joint Company Secretary | — | female |
| Yajuan Yan | Senior Vice President | — | female |
| Daidi Fan | Chief Scientific Officer | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2367.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
